| DrugRepV_0521 | Colchicine | Musculo-Skeletal System | Gout | Ebola virus | EBOVBlaVP40 | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26038505 |
| DrugRepV_0562 | Proglumetacin | Musculo-Skeletal System | Inflammatory disorders | Ebola virus | EBOVBlaVP40 | NA | Fluorescence-based assay | Decrease (50 %) | Experimental | 26038505 |
| DrugRepV_0732 | Probenecid | Musculo-Skeletal System | Gout | Influenza virus | A/WSN/33 |  | Fluorescence-based assay | Decrease (50 %) | Approved, Investigational | 23129053 |
| DrugRepV_0733 | Probenecid | Musculo-Skeletal System | Gout | Influenza virus | A/WSN/33 | | Fluorescence-based assay | Decrease (3 Fold) | Approved, Investigational | 23129053 |
| DrugRepV_0734 | Probenecid | Musculo-Skeletal System | Gout | Influenza virus | A/New/ Caledonia/20/99 | | Fluorescence-based assay | Decrease (50 %) | Approved, Investigational | 23129053 |
| DrugRepV_0735 | Probenecid | Musculo-Skeletal System | Gout | Influenza virus | A/California/07/09 | | Fluorescence-based assay | Decrease (25 %) | Approved, Investigational | 23129053 |
| DrugRepV_0736 | Probenecid | Musculo-Skeletal System | Gout | Influenza virus | A/Philippines/2/82/X-79 | | Fluorescence-based assay | Decrease (15 %) | Approved, Investigational | 23129053 |
| DrugRepV_0737 | Probenecid | Musculo-Skeletal System | Gout | Influenza virus | A/WSN/33 | | Real-time PCR | Decrease (>4 Fold) | Approved, Investigational | 23129053 |
| DrugRepV_0738 | Probenecid | Musculo-Skeletal System | Gout | Influenza virus | A/New/ Caledonia/20/99 | | Real-time PCR | Decrease (~10 Fold) | Approved, Investigational | 23129053 |
| DrugRepV_0739 | Probenecid | Musculo-Skeletal System | Gout | Influenza virus | A/California/04/09 | | Real-time PCR | Decrease (2 Fold) | Approved, Investigational | 23129053 |
| DrugRepV_0740 | Probenecid | Musculo-Skeletal System | Gout | Influenza virus | A/WSN/33 | | TCID50 assay | Decrease (>3 Log10 TCID50) | Approved, Investigational | 23129053 |
| DrugRepV_0741 | Probenecid | Musculo-Skeletal System | Gout | Influenza virus | A/New/ Caledonia/20/99 | | TCID50 assay | Decrease (2 Log10 TCID50) | Approved, Investigational | 23129053 |
| DrugRepV_0742 | Probenecid | Musculo-Skeletal System | Gout | Influenza virus | A/California/04/09 | | TCID50 assay | Decrease (>1 Log10 TCID50) | Approved, Investigational | 23129053 |
| DrugRepV_0743 | Probenecid | Musculo-Skeletal System | Gout | Influenza virus | A/WSN/33 | | NA | Increase | Approved, Investigational | 23129053 |
| DrugRepV_0779 | Auranofin | Musculo-Skeletal System | Rheumatoid arthritis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (93.84 %) | Approved | 27476412 |
| DrugRepV_0812 | Colchicine | Musculo-Skeletal System | Gout | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (65.075 %) | Approved | 27476412 |
| DrugRepV_0834 | Cisatracurium Besylate | Musculo-Skeletal System | Muscle spasms | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (59.815 %) | Approved | 27476412 |
| DrugRepV_0872 | Probenecid | Musculo-Skeletal System | Gout | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (51.465 %) | Approved, Investigational | 27476412 |
| DrugRepV_0891 | Chlorzoxazone | Musculo-Skeletal System | Pain | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (54.755 %) | Approved | 27476412 |
| DrugRepV_0917 | Etodolac | Musculo-Skeletal System | Osteoarthritis and rheumatoid arthritis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (54.89 %) | Approved | 27476412 |
| DrugRepV_0942 | Meclofenamate Sodium | Musculo-Skeletal System | Pain | Primary dysmenorrhea | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (50.11 %) | Approved, Vet approved | 27476412 |
| DrugRepV_0946 | Sulindac | Musculo-Skeletal System | Osteoarthritis | Rheumatoid arthritis | Ankylosing spondylitis | Acute painful shoulder | Acute gouty arthritis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (51.295 %) | Approved, Investigational | 27476412 |
| DrugRepV_0952 | Febuxostat | Musculo-Skeletal System | Hyperuricemia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (55.325 %) | Approved | 27476412 |
| DrugRepV_0980 | Zoledronic Acid Monohydrate | Musculo-Skeletal System | Hypercalcemia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (54.625 %) | Approved | 27476412 |
| DrugRepV_0990 | Ibuprofen | Musculo-Skeletal System | Rheumatoid arthritis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (52.025 %) | Approved | 27476412 |
| DrugRepV_1019 | Tolmetin Sodium Dihydrate | Musculo-Skeletal System | Rheumatoid arthritis and osteoarthritis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (51.77 %) | Approved | 27476412 |
| DrugRepV_1025 | Pancuronium Dibromide | Musculo-Skeletal System | Muscle relaxant during anesthesia and surgical procedures | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (54.955 %) | Approved | 27476412 |
| DrugRepV_1071 | Fenoprofen Calcium | Musculo-Skeletal System | Rheumatoid arthritis | Osteoarthritis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (49.89 %) | Approved | 27476412 |
| DrugRepV_1094 | Succinylcholine Chloride Dihydrate | Musculo-Skeletal System | Muscle spasms (Muscle Relaxant) | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (50.005 %) | Approved | 27476412 |
| DrugRepV_1101 | Ketoprofen | Musculo-Skeletal System | Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Dysmenorrhea | Pain (sprains and strains, postoperative (including dental surgery) or postpartum pain) | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (52.115 %) | Approved, Vet approved | 27476412 |
| DrugRepV_1130 | Ketorolac Tromethamine | Musculo-Skeletal System | Osteoarthritis | Severe Pain | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (49.06 %) | Approved | 27476412 |
| DrugRepV_1170 | Oxaprozin | Musculo-Skeletal System | Inflammation | Swelling | Stiffness | Joint pain associated with rheumatoid arthritis and osteoarthritis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (50.255 %) | Approved | 27476412 |
| DrugRepV_1192 | Etidronate Disodium | Musculo-Skeletal System | Paget disease | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.165 %) | Approved | 27476412 |
| DrugRepV_1203 | Meloxicam | Musculo-Skeletal System | Arthritis | Osteoarthritis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (51.475 %) | Approved, Vet approved | 27476412 |
| DrugRepV_1210 | Naproxen | Musculo-Skeletal System | Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Polyarticular juvenile idiopathic arthritis | Tendinitis | Bursitis | Acute gout | Primary dysmenorrhea | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.73 %) | Approved | 27476412 |
| DrugRepV_1218 | Methocarbamol | Musculo-Skeletal System | Muscle spasms | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.16 %) | Approved, Vet approved | 27476412 |
| DrugRepV_1248 | Atracurium Besylate | Musculo-Skeletal System | Endotracheal intubation | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (48.525 %) | Approved | 27476412 |
| DrugRepV_1265 | Baclofen | Musculo-Skeletal System | Muscle spasms | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (49.605 %) | Approved | 27476412 |
| DrugRepV_1268 | Guanidine Hydrochloride | Musculo-Skeletal System | Muscle weakness | Myasthenic syndrome of Eaton-Lambert | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (44.91 %) | Approved | 27476412 |
| DrugRepV_1289 | Mefenamic Acid | Musculo-Skeletal System | Rheumatoid arthritis | Osteoarthritis | Dysmenorrhea, and mild to moderate pain, inflammation, and fever | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (46.43 %) | Approved | 27476412 |
| DrugRepV_1299 | Vecuronium bromide | Musculo-Skeletal System | Non-depolarizing neuromuscular blocking agent | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (50.6 %) | Approved | 27476412 |
| DrugRepV_1303 | Piroxicam | Musculo-Skeletal System | Osteoarthritis | Rheumatoid arthritis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (50.81 %) | Approved, Investigational | 27476412 |
| DrugRepV_1308 | Penicillamine | Musculo-Skeletal System | Wilson disease | Cystinuria | Active rheumatoid arthritis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (42.665 %) | Approved | 27476412 |
| DrugRepV_1315 | Flurbiprofen | Musculo-Skeletal System | Rheumatoid arthritis | Osteorarthritis | Anklosing spondylitis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (44.215 %) | Approved, Investigational | 27476412 |
| DrugRepV_1334 | Pamidronic Acid | Musculo-Skeletal System | Hypercalcemia associated with malignancy | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (48 %) | Approved | 27476412 |
| DrugRepV_1336 | Ibandronate Sodium Monohydrate | Musculo-Skeletal System | Osteoporosis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (45.185 %) | Approved | 27476412 |
| DrugRepV_1378 | Tizanidine Hydrochloride | Musculo-Skeletal System | Muscle spasms | Multiple sclerosis | Stroke | Acquired brain injury or a Spinal cord injury | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (51.39 %) | Approved, Investigational | 27476412 |
| DrugRepV_1379 | Risedronic Acid | Musculo-Skeletal System | Paget's disease | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (40.505 %) | Approved | 27476412 |
| DrugRepV_1386 | Dantrolene Sodium | Musculo-Skeletal System | Malignant hyperthermia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (45.04 %) | Approved | 27476412 |
| DrugRepV_1422 | Allopurinol | Musculo-Skeletal System | Hyperuricemia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (43.775 %) | Approved | 27476412 |
| DrugRepV_1438 | Rocuronium Bromide | Musculo-Skeletal System | Muscle fasciculation caused by succinylcholine | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (45.025 %) | Approved | 27476412 |
| DrugRepV_1446 | Orphenadrine Citrate | Musculo-Skeletal System | Parkinson's disease | Muscle spasm | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (42.71 %) | Approved | 27476412 |
| DrugRepV_1462 | Nabumetone | Musculo-Skeletal System | Rheumatoid arthritis | Osteoarthritis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (42.66 %) | Approved | 27476412 |
| DrugRepV_1477 | Alendronate Sodium trihydrate | Musculo-Skeletal System | Paget disease | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (42.805 %) | Approved | 27476412 |
| DrugRepV_1481 | Cyclobenzaprine Hydrochloride | Musculo-Skeletal System | Muscle spasms | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (37.705 %) | Approved | 27476412 |
| DrugRepV_1526 | Celecoxib | Musculo-Skeletal System | Osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, acute pain, and primary dysmenorrhea | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (29.635 %) | Approved | 27476412 |
| DrugRepV_1656 | Febuxostat | Musculo-Skeletal System | Hyperuricemia | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1667 | Tiaprofenic Acid | Musculo-Skeletal System | Arthritic pain | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1668 | Flufenamic Acid | Musculo-Skeletal System | Musculoskeletal | Joint disorders | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1680 | Diacerein | Musculo-Skeletal System | Osteoarthritis | Zika virus | MR766 | NA | Cell viability assay | Decrease (35.2 %) | Approved | 27571349 |
| DrugRepV_1683 | Suprofen | Musculo-Skeletal System | Miosis (pupil constriction) | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved, Withdrawn | 27571349 |
| DrugRepV_1684 | Ketorolac Tromethamine | Musculo-Skeletal System | Osteoarthritis | Severe Pain | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1691 | Fenbufen | Musculo-Skeletal System | Inflammatory disorders (in osteoarthritis, ankylosing spondylitis, and tendinitis) | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1710 | Flurbiprofen Axetil | Musculo-Skeletal System | Hyperalgesia | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1727 | Febuxostat | Musculo-Skeletal System | Hyperuricemia | Zika virus | MR766 | NA | Cell viability assay | Decrease (68.4 %) | Approved | 27571349 |
| DrugRepV_1738 | Tiaprofenic Acid | Musculo-Skeletal System | Arthritic pain | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1739 | Flufenamic Acid | Musculo-Skeletal System | Musculoskeletal | Joint disorders | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1751 | Diacerein | Musculo-Skeletal System | Osteoarthritis | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1754 | Suprofen | Musculo-Skeletal System | Miosis (pupil constriction) | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved, Withdrawn | 27571349 |
| DrugRepV_1755 | Ketorolac Tromethamine | Musculo-Skeletal System | Osteoarthritis | Severe Pain | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1762 | Fenbufen | Musculo-Skeletal System | Inflammatory disorders (in osteoarthritis, ankylosing spondylitis, and tendinitis) | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1781 | Flurbiprofen Axetil | Musculo-Skeletal System | Hyperalgesia | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1798 | Febuxostat | Musculo-Skeletal System | Hyperuricemia | Zika virus | MR766 | NA | Cell viability assay | No significant effect | Approved | 27571349 |
| DrugRepV_1809 | Tiaprofenic Acid | Musculo-Skeletal System | Arthritic pain | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1810 | Flufenamic Acid | Musculo-Skeletal System | Musculoskeletal | Joint disorders | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1822 | Diacerein | Musculo-Skeletal System | Osteoarthritis | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1825 | Suprofen | Musculo-Skeletal System | Miosis (pupil constriction) | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved, Withdrawn | 27571349 |
| DrugRepV_1826 | Ketorolac Tromethamine | Musculo-Skeletal System | Osteoarthritis | Severe Pain | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1833 | Fenbufen | Musculo-Skeletal System | Inflammatory disorders (in osteoarthritis, ankylosing spondylitis, and tendinitis) | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1852 | Flurbiprofen Axetil | Musculo-Skeletal System | Hyperalgesia | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_2027 | Indoprofen | Musculo-Skeletal System | Inflammatory disease | Ebola virus | Zaire strain-pEBOV | NA | Firefly luciferase assay | Decrease (50 %) | Withdrawn | 26585243 |
| DrugRepV_2064 | Niflumic Acid | Musculo-Skeletal System | Rheumatoid arthritis | Chikungunya virus | S27 | NA | Microneutralization assay | No significant decrease | Approved | 27742486 |
| DrugRepV_2065 | Tolfenamic Acid | Musculo-Skeletal System | Pain associated with the acute attack of migraines | Chikungunya virus | S27 | NA | Microneutralization assay | No significant decrease | Approved, Investigational | 27742486 |
| DrugRepV_2158 | Tolfenamic Acid | Musculo-Skeletal System | Pain associated with the acute attack of migraines | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Decrease (91.0134313 %) | Approved, Investigational | 27742486 |
| DrugRepV_2168 | Nimesulide | Musculo-Skeletal System | Acute pain | Symptomatic treatment of osteoarthritis | Primary dysmenorrhoea | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (39.2301835 %) | Approved, Investigational, Withdrawn | 27742486 |
| DrugRepV_2169 | Acemetacin | Musculo-Skeletal System | Acute inflammation of the joints - Analgesic and antipyretic | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (39.1366729 %) | Approved | 27742486 |
| DrugRepV_2185 | Etidronate | Musculo-Skeletal System | Paget disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (13.5390608 %) | Approved | 27742486 |
| DrugRepV_2217 | Etodolac | Musculo-Skeletal System | Osteoarthritis and rheumatoid arthritis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.54969898 %) | Approved | 27742486 |
| DrugRepV_2222 | Fenoprofen Calcium | Musculo-Skeletal System | Rheumatoid arthritis | Osteoarthritis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.30740883 %) | Approved | 27742486 |
| DrugRepV_2250 | Celecoxib | Musculo-Skeletal System | Osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, acute pain, and primary dysmenorrhea | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.89285907 %) | Approved | 27742486 |
| DrugRepV_2251 | Ibandronate Sodium | Musculo-Skeletal System | Osteoporosis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.8438752 %) | Approved, Investigational | 27742486 |
| DrugRepV_2268 | Pancuronium | Musculo-Skeletal System | Muscle relaxant during anesthesia and surgical procedures | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.07557498 %) | Approved | 27742486 |
| DrugRepV_2278 | Cisatracurium Besylate | Musculo-Skeletal System | Muscle spasms | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.8029401 %) | Approved | 27742486 |
| DrugRepV_2284 | Naproxen | Musculo-Skeletal System | Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Polyarticular juvenile idiopathic arthritis | Tendinitis | Bursitis | Acute gout | Primary dysmenorrhea | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.70566399 %) | Approved | 27742486 |
| DrugRepV_2335 | Lornoxicam | Musculo-Skeletal System | Pain | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.49164883 %) | Approved, Investigational | 27742486 |
| DrugRepV_2362 | Allopurinol Sodium | Musculo-Skeletal System | Hyperuricemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.87428814 %) | Approved | 27742486 |
| DrugRepV_2387 | Risedronic Acid | Musculo-Skeletal System | Paget's disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.38707257 %) | Approved | 27742486 |
| DrugRepV_2402 | Strontium Ranelate | Musculo-Skeletal System | Osteoporosis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.19592095 %) | Approved, Withdrawn | 27742486 |
| DrugRepV_2412 | Meloxicam | Musculo-Skeletal System | Arthritis | Osteoarthritis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.96940127 %) | Approved, Vet approved | 27742486 |
| DrugRepV_2430 | Sulindac | Musculo-Skeletal System | Osteoarthritis | Rheumatoid arthritis | Ankylosing spondylitis | Acute painful shoulder | Acute gouty arthritis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.66082495 %) | Approved, Investigational | 27742486 |
| DrugRepV_2433 | Rocuronium Bromide | Musculo-Skeletal System | Muscle fasciculation caused by succinylcholine | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.57246722 %) | Approved | 27742486 |
| DrugRepV_2441 | Zoledronic Acid | Musculo-Skeletal System | Hypercalcemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.32603653 %) | Approved | 27742486 |
| DrugRepV_2444 | Pamidronate Disodium | Musculo-Skeletal System | Hypercalcemia associated with malignancy | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.23979587 %) | Approved | 27742486 |
| DrugRepV_2461 | Tenoxicam | Musculo-Skeletal System | Rheumatoid arthritis | Osteoarthritis | Backache | Pain | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.85680778 %) | Approved | 27742486 |
| DrugRepV_2490 | Risedronate Sodium | Musculo-Skeletal System | Paget's disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.24157209 %) | Approved, Investigational | 27742486 |
| DrugRepV_2504 | Tizanidine Hydrochloride | Musculo-Skeletal System | Muscle spasms | Multiple sclerosis | Stroke | Acquired brain injury or a Spinal cord injury | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.04828156 %) | Approved, Investigational | 27742486 |
| DrugRepV_2509 | Niflumic Acid | Musculo-Skeletal System | Rheumatoid arthritis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Decrease (100 %) | Approved | 27742486 |
| DrugRepV_2532 | Methocarbamol | Musculo-Skeletal System | Muscle spasms | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.5777085 %) | Approved, Vet approved | 27742486 |
| DrugRepV_2547 | Orphenadrine Citrate | Musculo-Skeletal System | Parkinson disease and Muscle spasm | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.8107955 %) | Approved | 27742486 |
| DrugRepV_2579 | Chlormezanone | Musculo-Skeletal System | Anxiety and muscle spasm | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.3558347 %) | Approved | 27742486 |
| DrugRepV_2582 | Vecuronium bromide | Musculo-Skeletal System | Non-depolarizing neuromuscular blocking agent | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.3726313 %) | Approved | 27742486 |
| DrugRepV_2603 | Suprofen | Musculo-Skeletal System | Miosis (pupil constriction) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.6028527 %) | Approved, Withdrawn | 27742486 |
| DrugRepV_2639 | Gallamine triethiodide | Musculo-Skeletal System | Anesthesia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.0196399 %) | Approved | 27742486 |
| DrugRepV_2658 | Febuxostat | Musculo-Skeletal System | Hyperuricemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.3323109 %) | Approved | 27742486 |
| DrugRepV_2712 | (R)-Baclofen | Musculo-Skeletal System | Spasticity in multiple sclerosis, autism spectrum disorder, and social withdrawal in fragile X syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.1299275 %) | Approved | 27742486 |
| DrugRepV_2778 | Ketorolac | Musculo-Skeletal System | Osteoarthritis | Severe Pain | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.5175573 %) | Approved | 27742486 |
| DrugRepV_2790 | Flurbiprofen | Musculo-Skeletal System | Rheumatoid arthritis | Osteorarthritis | Anklosing spondylitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.7319021 %) | Approved, Investigational | 27742486 |
| DrugRepV_2796 | Ibuprofen lysine | Musculo-Skeletal System | Rheumatoid arthritis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.8737995 %) | Approved | 27742486 |
| DrugRepV_2812 | Piroxicam | Musculo-Skeletal System | Osteoarthritis | Rheumatoid arthritis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.3800641 %) | Approved, Investigational | 27742486 |
| DrugRepV_2845 | Atracurium Besylate | Musculo-Skeletal System | Endotracheal intubation | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.50194 %) | Approved | 27742486 |
| DrugRepV_2874 | Allopurinol | Musculo-Skeletal System | Hyperuricemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-8.0088421 %) | Approved | 27742486 |
| DrugRepV_2877 | Fenoprofen Calcium Hydrate | Musculo-Skeletal System | Rheumatoid arthritis | Osteoarthritis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-8.1318763 %) | Approved | 27742486 |
| DrugRepV_2898 | Ketoprofen | Musculo-Skeletal System | Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Dysmenorrhea | Pain (sprains and strains, postoperative (including dental surgery) or postpartum pain) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-9.0969554 %) | Approved, Vet approved | 27742486 |
| DrugRepV_2899 | Bufexamac | Musculo-Skeletal System | Eczema and dermatoses | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-9.1032426 %) | Approved | 27742486 |
| DrugRepV_2905 | Rofecoxib | Musculo-Skeletal System | Osteoarthritis | Rheumatoid arthritis | Acute pain in adults | Primary dysmenorrhea | Acute treatment of migraine attacks with or without auras | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-9.4168988 %) | Approved | 27742486 |
| DrugRepV_2923 | Phenylbutazone | Musculo-Skeletal System | Backache | Ankylosing spondylitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-11.578798 %) | Approved, Vet approved | 27742486 |
| DrugRepV_2925 | Ibuprofen | Musculo-Skeletal System | Rheumatoid arthritis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-11.93197 %) | Approved | 27742486 |
| DrugRepV_2926 | Alendronate | Musculo-Skeletal System | Paget disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-11.958789 %) | Approved | 27742486 |
| DrugRepV_3323 | Naproxen | Musculo-Skeletal System | Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Polyarticular juvenile idiopathic arthritis | Tendinitis | Bursitis | Acute gout | Primary dysmenorrhea | Influenza virus | A/WSN/33 | | MTT assay | Decrease (50 %) | Approved | 23459490 |
| DrugRepV_3324 | Naproxen | Musculo-Skeletal System | Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Polyarticular juvenile idiopathic arthritis | Tendinitis | Bursitis | Acute gout | Primary dysmenorrhea | Influenza virus | A/WSN/33 | | Plaque assay | Decrease (50 %) | Approved | 23459490 |
| DrugRepV_3325 | Naproxen | Musculo-Skeletal System | Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Polyarticular juvenile idiopathic arthritis | Tendinitis | Bursitis | Acute gout | Primary dysmenorrhea | Influenza virus | A/WSN/33 | | Real-time PCR | Decrease (50 %) | Approved | 23459490 |
| DrugRepV_3326 | Naproxen | Musculo-Skeletal System | Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Polyarticular juvenile idiopathic arthritis | Tendinitis | Bursitis | Acute gout | Primary dysmenorrhea | Influenza virus | A/WSN/33 | | Plaque assay | Decrease (2.5 Log) | Approved | 23459490 |
| DrugRepV_3327 | Naproxen | Musculo-Skeletal System | Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Polyarticular juvenile idiopathic arthritis | Tendinitis | Bursitis | Acute gout | Primary dysmenorrhea | Influenza virus | UDORN/72 | | Plaque assay | Decrease (2.5 Log) | Approved | 23459490 |
| DrugRepV_3328 | Naproxen | Musculo-Skeletal System | Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Polyarticular juvenile idiopathic arthritis | Tendinitis | Bursitis | Acute gout | Primary dysmenorrhea | Influenza virus | A/PR8 | | Plaque assay | Decrease (1.5 Log) | Approved | 23459490 |
| DrugRepV_3356 | Naproxen | Musculo-Skeletal System | Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Polyarticular juvenile idiopathic arthritis | Tendinitis | Bursitis | Acute gout | Primary dysmenorrhea | Influenza virus | A/WSN/33 | | Cell viability assay | Decrease (50 %) | Approved | 30028133 |
| DrugRepV_3357 | Naproxen | Musculo-Skeletal System | Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Polyarticular juvenile idiopathic arthritis | Tendinitis | Bursitis | Acute gout | Primary dysmenorrhea | Influenza virus | A/Udorn/72 | | Plaque assay | Decrease (50 %) | Approved | 30028133 |
| DrugRepV_3358 | Naproxen | Musculo-Skeletal System | Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Polyarticular juvenile idiopathic arthritis | Tendinitis | Bursitis | Acute gout | Primary dysmenorrhea | Influenza virus | A/Udorn/72 | | Cell viability assay | Decrease (50 %) | Approved | 30028133 |
| DrugRepV_3359 | Naproxen | Musculo-Skeletal System | Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Polyarticular juvenile idiopathic arthritis | Tendinitis | Bursitis | Acute gout | Primary dysmenorrhea | Influenza virus | A/PR/8/34 | | Survival assay | Increase | Approved | 30028133 |
| DrugRepV_3360 | Naproxen | Musculo-Skeletal System | Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Polyarticular juvenile idiopathic arthritis | Tendinitis | Bursitis | Acute gout | Primary dysmenorrhea | Influenza virus | A/PR/8/34 | | Plaque assay | No significant effect (0.5 Log) | Approved | 30028133 |
| DrugRepV_3366 | Flufenamic Acid | Musculo-Skeletal System | Musculoskeletal | Joint disorders | Influenza virus | A/ WSN/1933 (H1N1) | | High-throughput screening | Decrease (50 %) | Approved | 24096239 |
| DrugRepV_3367 | Tolfenamic Acid | Musculo-Skeletal System | Pain associated with the acute attack of migraines | Influenza virus | A/ WSN/1933 (H1N1) | | High-throughput screening | Decrease (50 %) | Approved, Investigational | 24096239 |
| DrugRepV_3368 | Mefenamic Acid | Musculo-Skeletal System | Rheumatoid arthritis | Osteoarthritis | Dysmenorrhea, and mild to moderate pain, inflammation, and fever | Influenza virus | A/ WSN/1933 (H1N1) | | High-throughput screening | Decrease (50 %) | Approved | 24096239 |
| DrugRepV_3369 | Meclofenamate sodium | Musculo-Skeletal System | Pain | Primary dysmenorrhea | Influenza virus | A/ WSN/1933 (H1N1) | | High-throughput screening | Decrease (50 %) | Approved, Vet approved | 24096239 |
| DrugRepV_4010 | Dantrolene | Musculo-Skeletal System | Malignant hyperthermia | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4019 | Dantrolene | Musculo-Skeletal System | Malignant hyperthermia | Nipah virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_5218 | Guanidine | Musculo-Skeletal System | Muscle weakness | Myasthenic syndrome of Eaton-Lambert | Rift Valley fever virus | RVF-VLPs | NA | RLuc expression | No significant effect (54.2 %) | Approved | 21994655 |
| DrugRepV_6211 | Mefenamic acid | Musculo-Skeletal System | Rheumatoid arthritis | Osteoarthritis | Dysmenorrhea, and mild to moderate pain, inflammation, and fever | Dengue virus | NA | | Virus inhibition assay | Decrease (50 %) | Approved | 24522138 |
| DrugRepV_6212 | Tolfenamic acid | Musculo-Skeletal System | Pain associated with the acute attack of migraines | Dengue virus | NA | | Virus inhibition assay | Decrease (27.6 ± 3.7 %) | Approved, Investigational | 24522138 |
| DrugRepV_6213 | Flufenamic Acid | Musculo-Skeletal System | Musculoskeletal | Joint disorders | Dengue virus | NA | | Virus inhibition assay | Decrease (15.2 ± 1.1 %) | Approved | 24522138 |
| DrugRepV_6214 | Meclofenamic acid | Musculo-Skeletal System | Pain | Primary dysmenorrhea | Dengue virus | NA | | Virus inhibition assay | Decrease (19.4 ± 2.2 %) | Approved, Vet approved | 24522138 |
| DrugRepV_7787 | Auranofin | Musculo-Skeletal System | Rheumatoid arthritis | SARS Coronavirus-2 | USA-WA1/2020 | NA | qRT-PCR | Decrease (50 %) | Approved | 32442105 |